| | |
ASPsiRNA information |
siRNA Id: | aspsirna0428
|
siRNA Name: | P1
|
Mismatch information |
Wild siRNA (As strand 3'->5'): | GACCAACCAUUUCGGAGUC
|
ASP-siRNA (As strand 3'->5'): | CACCAACCAUUUCGGAGUC
|
Mismatch position in siRNA: | C19G |
Gene Information |
Gene Name | Presenilin1 (PSEN1) |
Target Sequence (5'->3'): | UUCAUUUUCUACAGUGUUCUGGUUGGUAAAGCCUCAG
|
Wild allele (5'->3'): | CUGGUUGGUAAAGCCUCAG
|
Mutant allele (5'->3'): | GUGGUUGGUAAAGCCUCAG
|
Position of siRNA on target gene: | 1458-1476
|
Respective Gene/Protein Resources |
GenBank Accession: | NM_000021.3 |
Cytogenic location: | 14q24.2 |
Chromosomal coordinates: | 14:73,603,142-73,690,398 |
UniProt ID: | P49768 |
HUGO ID: | 9508 |
Reference SNp(RefSNP): | rs63750886 |
Disease/Mutation information |
Target Mutation: | c.811C>G, p.Leu271Val
|
Matation type/variant: | Single nucleotide variant/Missense variant
|
Mutation at gene level: | NG_007386.2:g.66602C>G
|
Pathogenic status of mutation: | Pathogenic
|
Disease: | Alzheimers disease |
Clinical Resources |
ClinVar ID: | 98106 |
KEGG disease ID: | H00056 |
OMIM ID: | 104300 |
COSMIC: | PSEN1 |
DECIPHER: | PSEN1 |
GeneTests: | PSEN1 |
ASP siRNA details |
Mutant allele (5'->3'): | GUGGUUGGUAAAGCCUCAG
|
ASP-siRNA (As strand 3'->5'): | CACCAACCAUUUCGGAGUC
|
Percentage efficacy of ASP-siRNA for mutant allele: | 63
|
Wild allele (5'->3'): | CUGGUUGGUAAAGCCUCAG
|
ASP-siRNA (As strand 3'->5'): | CACCAACCAUUUCGGAGUC
|
Percentage efficacy of ASP-siRNA for wild allele: | 93
|
Relative difference: | -30
|
Wild siRNA details |
Wild allele (5'->3'): | CUGGUUGGUAAAGCCUCAG
|
Wild siRNA (As strand 3'->5'): | GACCAACCAUUUCGGAGUC
|
Percentage efficacy of wild siRNA for wild allele: | NA
|
Wild allele (5'->3'): | CUGGUUGGUAAAGCCUCAG
|
ASP-siRNA (As strand 3'->5'): | CACCAACCAUUUCGGAGUC
|
Percentage efficacy of Wild sirna for mutant allele: | NA
|
Relative difference : | NA
|
General information |
Mismatch incorporated in siRNA/Target: | siRNA |
Cell-line used: | HeLa |
Experimental technique used: | Dual luciferase reporter assay |
Transfection method: | Lipofectamine 2000 |
siRNA expression method: | Chemically synthesized (Phosphoramidite method) |
Post-transfection duration: | 48 hours |
Concentration used: | 1.5microL |
Reference: | 21559198 |
Delivery method: | Transfection |
'Article title: | Specific Silencing of L392V PSEN1 Mutant Allele by RNA Interference. |
'Authors: | Sierant M, Paduszynska A, Kazmierczak-Baranska J, Nacmias B, Sorbi S, Bagnoli S, Sochacka E, Nawrot B. |
'Journal Reference: | Int J Alzheimers Dis. 2011 Apr 7;2011:809218. doi: 10.4061/2011/809218. |
'